Top 20 Pharma and BioPharma Companies

Top 20 Pharma and Biopharma Report

Top 20 Pharma and Biopharma Report

Big Pharma continues to face the impact of competitive pressures, fluctuating currencies, the patent cliff, and pipeline surprises, all of which were reflected in financial results last year.  Payers around the world are demanding lower cost drugs and increased access to medicines, while stakeholders look for higher returns on their investment. Mergers and acquisitions, particularly those involving an offshore partner, continue to be seen, both as an easier way to augment a pipeline and as a tax-saving strategy, even though Pfizer’s $119-billion bid for AstraZeneca this Spring was rebuffed and Shire has also rejected AbbVie’s offers this Summer. Divestments and increased focus on core markets were the themes last year, and we can continue to see them play out in the future. Both Novartis and Pfizer unloaded their animal health care businesses to focus on human therapeutics. Companies are investing in developing economies and in biopharma, and forming strategic alliances, often with competitors, to achieve their goals. Exemplifying the trend was April’s business swap between Novartis and GSK, in which the companies traded vaccines and oncology businesses, and also built a new jointly owned consumer healthcare venture. Novartis came in as number one, because its generics and vaccine manufacturing business totals were included, for parity with other manufacturers where these businesses were considered in the total. Clearly, biopharmaceutical products play an increasingly pivotal role in Big Pharma’s drug pipelines. For example, Pfizer, which narrowly trailed Novartis as player Number Two this year, reports that biopharmaceuticals contributed 93% of its total revenues last year (94% of that figure in 2012 and 95% in 2011). Generics are becoming increasingly important, and, even before clear and harmonized global regulations take shape, companies are developing biosimilars pipelines. There is also a trend to investing in over-the-counter (OTC) markets, as more of yesteryear’s blockbusters are expected to be available directly to the consumer in the near future. In response to these changing realities, we have expanded our list slightly this year, to include pharma and biopharma companies, consumer healthcare divisions, and generics firms.Here is a quick look at key financial results. Some figures reported last year were adjusted in this year’s annual reports. This report is a very broad brush stroke view of trends, news and strategies based on developments this and last year.  We hope that you find it useful.

Top 20 Pharma and BioPharma Companies

RANK COMPANY LOCATION SALES
1
Abbvie
1 Waukegan Road North Chicago, Illinois 60064 US $18790 Billion
2
Baxter
1 Baxter Pkwy Deerfield, Illinois 60015 US $656.4 Billion
3
Novartis
Novartis Campus Basel, Baselstadt 4002 CH $57.9 Billion
4
Pfizer
66 Hudson Boulevard East, New York, New York, 10001-2192 $51.6 Billion
5
Sanofi
46 Avenue de la Grande Armee Paris, 75017 France $45.4 Billion
6
Merck
Rahway, NJ $44 Billion
7
Roche
Grenzacherstrasse Switzerland, 4070 CH $43.6 Billion
8
GlaxoSmithKline
980 Great West Road Brentford, Middlesex TW8 9GS GB $41.6 Billion
9
Johnson & Johnson
1 Johnson and Johnson Plaza, New Brunswick, NJ 08903 US $28.1 Billion
10
AstraZeneca
1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, Cambridgeshire CB2 0AA GB $25.7 Billion
11
Lilly
Lilly Corporate Center Indianapolis, Indiana 46285 US $23.1 Billion
12
Teva Pharmaceuticals
124 Dvora HaNevi'a St. Tel Aviv 6944020, Israel $20.3 Billion
13
Boehringer Ingelheim
900 Ridgefield Road, Ridgefield, CT 06877 $19.4 Billion
14
Amgen
One Amgen Center Drive Thousand Oaks, CA 91320 US $18.7 Billion
15
Bristol Myers Squibb
3401 Princeton Pike Lawrence Township, NJ 08648 US $16.4 Billion
16
Takeda
Japan $16.1 Billion
17
Novo Nordisk
Denmark $15.4 Billion
18
Bayer
Kaiser-Wilhelm-Allee Leverkusen, North Rhine-Westphalia 51373 DE $15.4 Billion
19
Merck inc.
Frankfurter Strasse 250 64293 Darmstadt Germany $15.3 Billion
20
Gilead Sciences
333 Lakeside Drive Foster City, CA 94404 US $11.2 Billion
21
Astellas
2375 Waterview Dr Northbrook, Illinois 60062 US $11.1 Billion
22
Daiichi Sankyo
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo Tokyo, 103-8426 JP $10.9 Billion
23
Actavis (now Allergan)
5 Giralda Farms, Dodge Dr, Madison, NJ 07940 $8.7 Billion
24
Biogen
225 Binney Street Cambridge, MA 02142 US $6.9 Billion
25
Mylan
1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 US $6.9 Billion